Catalent Pharma Solutions plans to invest $5 million to create a new drug development center of excellence at its Somerset headquarters, it announced Tuesday.
Catalent, a provider of solutions for drugs, biologics and consumer health products, said the investment in the 265,000 square foot development center will focus on preclinical to clinical solutions for orally delivered small molecules.
(FOR MORE from ROI-NJ on Catalent, click here.)
“This latest investment in Somerset will significantly strengthen our early development offering with focused formulation expertise and capacity for additional speed and flexibility,” said Jonathan Arnold, president of Catalent’s Oral Drug Delivery business unit. “It is highly complementary to Catalent’s West Coast facility in San Diego, California, and further positions Catalent as the strategic partner of choice for the early development of solid oral dose forms.”
The site currently has analytical labs, pilot and clinical stage equipment, and coating technologies for capsules, tablets, minitablets and multiparticulates.
